Biotechnology industries

Pharmaceutical industry

Metra Biosystems Announces Exclusive Research and Development Collaboration with Sumitomo Pharmaceuticals

Metra Biosystems, a leading international biomedical company, has announced an exclusive research and development collaboration with Sumitomo Pharmaceuticals for the development of bone-specific alkphase phosphatase. This collaboration marks a significant expansion of the existing relationship between the two companies, with Sumitomo Pharmaceuticals now having access to a complete panel of

Pharmaceutical industry

Corvas International Settles Lawsuit with Shareholder Class

Corvas International Inc., a biopharmaceutical company based in San Diego, has agreed to settle a lawsuit brought against the company, its directors, and Centocor Inc. by a plaintiff on behalf of a shareholder class. The lawsuit alleged that the defendants failed to disclose certain information related to Corvas' business

Drugs

North American Biologicals Secures $165 Million Contract with Pharmaceutical Division of Miles Inc.

North American Biologicals, Inc. (NABI) has been awarded a $165 million five-year plasma supply contract by the Pharmaceutical Division of Miles Inc. This contract replaces a pre-existing $35 million agreement, which had a remaining value of approximately $15 million. Under the terms of the new contract, NABI will supply Miles

Drugs

Viagene Reports Net Loss of $4.1 Million in Fourth Quarter 1994

Viagene, Inc., a biotechnology company based in San Diego, reported a net loss of $4.1 million for the fourth quarter ended December 31, 1994, surpassing the net loss of $1.7 million in the same quarter the previous year. The company's net loss for the year ended

Drugs

Somatix Therapy Corp. Acquires Merlin Pharmaceutical Corp.'s Gene Therapy Programs

Somatix Therapy Corp., a leader in gene therapy, has completed the acquisition of Merlin Pharmaceutical Corp.'s in vivo gene therapy programs and related intellectual property. The acquisition includes Merlin's adenoviral and adeno-associated viral vector technologies, which complement Somatix's proprietary retroviral vector technology. This strategic

Drugs

Amgen Wins Summary Judgment in Patent Dispute

Amgen, a global biotechnology company, has achieved a major victory in a patent dispute with Genetics Institute (GI). On February 14, 1995, a U.S. District Court in Massachusetts granted Amgen's motion for summary judgment, enforcing the Federal Circuit's prior judgment and barring GI from asserting

Drugs

Breakthrough in Alzheimer's Disease Research: Athena Neurosciences and Eli Lilly Develop New Animal Model

The development of a new animal model by Athena Neurosciences, Inc. and Eli Lilly and Company has marked a significant breakthrough in Alzheimer's disease research. This transgenic mouse model, now available for testing potential therapeutic agents, has been hailed as a major step forward in the fight against

Drugs

Ligand Pharmaceuticals and Glycomed Incorporated Announce Definitive Merger Agreement

Ligand Pharmaceuticals Inc. and Glycomed Incorporated, two leaders in the biotechnology sector, have announced a definitive merger agreement in a stock-for-stock transaction. The combined company would have a significant financial strength of approximately $100 million in cash and investments, as well as proprietary technologies focused on discovering and developing small

Pharmaceutical industry

Amgen Reports Strong Earnings Growth in 1994, Driven by Product Sales and Efficiency Gains

Thousand Oaks, CA-based Amgen Inc. announced on February 1, 1995, that its revenues increased by 21 percent to $443 million for the fourth quarter of 1994 and by 20 percent to $1.648 billion for the year. The company's strong earnings growth was driven by the success of

Drugs

Titan Pharmaceuticals Announces FDA Approval for Phase I Clinical Trial and Gene Therapy Studies

Titan Pharmaceuticals, a biopharmaceutical holding company, has announced that its operating companies, Ansan Inc. and Ingenex Inc., have received approval from the Food and Drug Administration (FDA) to initiate new clinical trials for cancer treatments. Ansan's Investigational New Drug (IND) application for AN-9, a novel anticancer agent, has

Pharmaceutical industry

Neurobiological Technologies Inc. Reports Second Quarter Net Loss

Neurobiological Technologies Inc., a biopharmaceutical company focused on the development of therapeutic products based on the interaction of the neuroendocrine and immune systems, announced a net loss of $1,226,000 for the second quarter ended December 31, 1994. This compares to a net loss of $750,000 for the

Drugs

Immunomedics Inc. Reports Financial Results for Quarter and Six-Month Period Ended December 31, 1994

Immunomedics Inc., a biopharmaceutical company, announced its financial results for the quarter and six-month period ended December 31, 1994. During this period, the company reported a net loss of $2.7 million, or $0.09 per share, with revenues of $0.8 million for the quarter. Compared to the same